Glenmark Lifesciences to double manufacturing capacity in five years

With formulation makers aiming at de-risk procurement by creating one more source for raw material other than China, the demand for APIs is rising, says company

Bulk drug player Glenmark Lifesciences, which is hitting the stock market with an initial public offering (IPO) next week, is betting on growing demand to more than double its current capacity over the next five years or so.

With many formulation makers (tablets, capsules, injectables, syrups etc) looking to de-risk their procurement strategy by creating one more source for raw material other than China, the demand for active pharmaceutical ingredients (APIs) is rising, says Yasir Rawjee, MD and CEO of Glenmark Lifesciences.

“We see a disproportionately high demand for our key APIs. We feel that this may be a result